Preclinical and Translational Study Design

The urgent need for new antitumor medications, driven by high cancer mortality rates and limited success of current treatments, necessitates a robust drug development process divided into preclinical and clinical phases. Preclinical research, fundamental in this process, involves pharmaceutical studies, drug formulation, and extensive pharmacological and toxicological analyses to establish safety and effective dosing. Guided by regulatory frameworks like those from the National Medical Products Administration and the International Council for Harmonisation, these studies are crucial for transitioning to clinical trials. Preclinical evaluation determines a drug’s safety profile, including safe starting doses and target organ identification, with an emphasis on quality and adaptability to novel drug properties. The outcomes of preclinical research significantly influence the design of clinical trials, with accurate documentation being vital for regulatory approval. This intricate blend of preclinical and clinical studies, aligned with global standards, is essential for developing effective antitumor medications.